Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 52

Epilepsy Clinical Trials Research and Development Pharmaceutical 52

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

WeedAdvisor

SEPTEMBER 24, 2019

GW Pharmaceuticals created the medication after studies showed surprising success treating severe childhood epilepsy, specifically Lennox-Gastaut Syndrome and Dravet Syndrome. study, the 26,000 Dravet and 130,000 LGS patients in Europe have a new alternative that could bring hope to a seemingly hopeless situation. In the U.S.,

Epilepsy 49

Epilepsy CBD Pharmaceutical Access 49

Cannabis Law Report

SEPTEMBER 29, 2022

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. The Therapeutic Goods Administration (TGA) issued 73 infringement notices totalling $972,360 between the medicinal cannabis companies MGC Pharmaceuticals Ltd, Cannatrek Ltd and Little Green Pharma Ltd.

Epilepsy 52

Epilepsy Conditions Media Medicine 52

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. In 2020, the law changed to allow patients with any medical condition to receive a doctor’s recommendation to use and purchase medical marijuana products containing a maximum 10 milligrams of THC.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. These compounds may help reduce symptoms and improve the quality of life for patients. The outcomes of these studies have had a profound impact on patient care.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

JULY 30, 2019

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. The US approval of Zogenix’s Fintepla, a potential competitor for GW’s drug, has been delayed but still lo… The European Pharmaceutical Review reports.

Epilepsy 40

Epilepsy Pharmaceutical Medicine Treatment 40

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Otherside Farms

JANUARY 24, 2019

Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. Although both studies will enroll 25 patients initially, the U.S. Source: FDA Approves Marijuana-Based Epilepsy Drug For Use On Kids In Clinical Trials. In the upcoming U.S.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. Thus, there is a great need to develop new and effective therapeutics for treating patients. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

MGC Pharma

NOVEMBER 1, 2017

This is a big moment for me and the MGC Pharmaceuticals team. Needless to say, I have been waiting a long time to write the following sentence: MGC Pharmaceuticals has just released their first product to the market. CannEpil™ is CBD-based medication that is used as a treatment for people with refractory epilepsy.

Epilepsy 100

Epilepsy Pharmaceutical Medicine CBD 100

Cannabis Law Report

JULY 12, 2019

Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

JANUARY 15, 2019

British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The patent, which has been embroiled in dispute since 2010, is for “the use of one or more cannabinoids in the treatment of epilepsy”.

Epilepsy 71

Epilepsy Cannabinoids Treatment Research and Development 71

MGC Pharma

APRIL 4, 2018

A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals. CBD-based treatment for people with Refractory Epilepsy?—?is Refractory Epilepsy is epilepsy that involves frequent and severe seizures that are difficult to treat. CannEpil™?—?CBD-based

Epilepsy 100

Epilepsy Pharmaceutical Research and Development CBD 100

CannaTech

JANUARY 16, 2019

Thanks to the recent emergence of regulated medical cannabis markets, the success of this versatile plant can be followed from farm to pharma and prescriber to patient, however, the origins of cannabis as medicine cannot be as simply traced as the plant is today from seed to sale. Of course, patients need product and product costs money.

Access 89

Access Patients Pharmaceutical Education 89

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

CannaTech

MAY 14, 2020

When I studied pharmaceutical science at Sydney University 24 years ago we were not taught about the Endocannabinoid System (ECS). Together the two courses taught me everything I need to know in order to knowledgeably counsel my patients on the correct use of cannabis medicine. I am a pharmacist.

Patients 59

Patients Epilepsy Education THC 59

CannaTech

MAY 14, 2020

When I studied pharmaceutical science at Sydney University 24 years ago we were not taught about the Endocannabinoid System (ECS). Together the two courses taught me everything I need to know in order to knowledgeably counsel my patients on the correct use of cannabis medicine. I am a pharmacist.

Patients 52

Patients Epilepsy Education THC 52

MMJ Recs

APRIL 1, 2024

Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment. Its non-addictive nature and minimal side effects make it an attractive alternative to conventional pharmaceuticals for many individuals seeking natural remedies.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

SEPTEMBER 20, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. About Virpax Pharmaceuticals.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. An estimated 250 patients a month are said to be prescribed cannabis medicines through the NHS compared to over 2,500 in the UK’s private sector. Step In Right Direction.

Data 52

Data Patients Clinical Trials Business 52

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Cannabis Law Report

AUGUST 4, 2022

Following the keenly anticipated June approval of its cannabis-derived Epidiolex, GW Pharmaceuticals $GWPH has finally launched the rare epilepsy drug in the United States. Most patients that suffer from these disorders require a host of seizure medications, and a majority are resistant to existing anti-epileptic therapies.

Epilepsy 52

Epilepsy Therapy Patients Treatment 52

Cannabis Law Report

DECEMBER 11, 2021

Families of patients in the most urgent need often have to resort to support from crowdfunding or from individual donors to keep their medicine going. And really patients having to crowdfund for private-prescribed medicine because they can’t get it on the NHS is just not right in this country.”. Read more at. Also see Labour List.

Treatment 52

Treatment Access Patients Medicine 52

The Fresh Toast

MARCH 5, 2020

In patients with rare forms of epilepsy, artisanal CBD increased seizures while pharmaceutical CBD caused seizure reduction. Continue reading You Should Reconsider Using Store-Bought CBD To Treat Seizures at The Fresh Toast.

CBD 52

CBD Epilepsy Pharmaceutical Patients 52

Cannabis Law Report

JULY 7, 2022

filed a petition requesting inter partes review of claims 1-13 of GW Pharmaceutical Ltd.’s s patent directed to the use of cannabinoids, including cannabidiol (“CBD”), in the treatment of certain types of epilepsy. GW Pharma Limited and Otsuka Pharmaceutical Co., Insys Development Company, Inc. IPR2017-00503, Paper No.

Epilepsy 52

Epilepsy Pharmaceutical Treatment Cannabinoids 52

Cannabis Law Report

NOVEMBER 15, 2021

–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. About Virpax Pharmaceuticals.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

United Patients Group

APRIL 18, 2023

Because they often combine it with other drugs like cocaine or heroin or even legal ‘prescribed’ pharmaceuticals–and those are far more dangerous than cannabis itself! In fact, there are some patients who prefer not to smoke because of their health conditions or other reasons. Myth: Cannabis is a cure-all.

Research and Development 116

Research and Development Indica Treatment Conditions 116

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. Though these tumors are noncancerous in nature, their presence can cause health problems, including epilepsy. What is Epidiolex?

Access 98

Access Epilepsy Treatment Conditions 98

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. “Our Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JULY 24, 2019

Our clinics are based on the premise that patients are treated by our world-renowned specialists in the relevant condition. We have the expertise to prescribe medicinal cannabis in a way that fits in with other more conventional treatments as and when we judge that to be in the best interest of the patients.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

The Cannigma

JUNE 1, 2021

Under the plan, some 3,000 patients in France will be treated with medical cannabis and monitored closely. Patients can take part if they have a medical condition which has not responded to pharmaceutical drugs. Patients can take part if they have a medical condition which has not responded to pharmaceutical drugs.

Law 115

Law Epilepsy Programs Patients 115